NCT05699811View on ClinicalTrials.gov

IFNα Expressing Mesenchymal Stromal Cells for Locally Advanced/Metastatic Solid Tumors

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

February 23, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions
Locally Advanced or Metastatic Solid Tumors
Interventions
BIOLOGICAL

MSC-IFNα

MSC-IFNα form a dose of 2×10\^6 cells/kg, intravenous infusion every 4-6 weeks

DRUG

Nab paclitaxel

125mg/m2, intravenous infusion every 4-6 weeks

DRUG

Cyclophosphamide

200mg/m2, intravenous infusion every 4-6 weeks

DRUG

Anti-PD-1 monoclonal antibody

200mg, intravenous infusion every 4-6 weeks

Trial Locations (1)

Unknown

RECRUITING

Department of Biotherapeutic, Chinese PLA General Hospital, Beijing

All Listed Sponsors
collaborator

Wuxi Sinotide New Drug Discovery Institutes

UNKNOWN

lead

Chinese PLA General Hospital

OTHER